<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">MD-Onco</journal-id><journal-title-group><journal-title xml:lang="en">MD-Onco</journal-title><trans-title-group xml:lang="ru"><trans-title>MD-Onco</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2782-3202</issn><issn publication-format="electronic">2782-6171</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">41</article-id><article-id pub-id-type="doi">10.17650/2782-3202-2022-2-3-21-27</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RARE NEOPLASMS: COMPLEX CLINICAL SITUATIONS AND SELECTION OF TREATMENT TACTICS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>РЕДКИЕ НОВООБРАЗОВАНИЯ: СЛОЖНЫЕ КЛИНИЧЕСКИЕ СИТУАЦИИ И ВЫБОР ТАКТИКИ ЛЕЧЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Neoadjuvant immunotherapy in treatment of oligometastatic locally advanced colon cancer. Clinical case</article-title><trans-title-group xml:lang="ru"><trans-title>Неоадъювантная иммунотерапия в лечении олигометастатического местно-распространенного рака ободочной кишки. Клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5565-615X</contrib-id><name-alternatives><name xml:lang="en"><surname>Rasulov</surname><given-names>A. O.</given-names></name><name xml:lang="ru"><surname>Расулов</surname><given-names>А. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9992-3822</contrib-id><name-alternatives><name xml:lang="en"><surname>Madyarov</surname><given-names>J. M.</given-names></name><name xml:lang="ru"><surname>Мадьяров</surname><given-names>Ж. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Jasur M. Madyarov</bold> </p><p><italic>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><bold>Жасур Махирович Мадьяров</bold></p><p><italic>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</italic></p></bio><email>jasur2001@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3024-9283</contrib-id><name-alternatives><name xml:lang="en"><surname>Kulikov</surname><given-names>A. E.</given-names></name><name xml:lang="ru"><surname>Куликов</surname><given-names>А. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2306-407X</contrib-id><name-alternatives><name xml:lang="en"><surname>Rasulov</surname><given-names>Z. R.</given-names></name><name xml:lang="ru"><surname>Расулов</surname><given-names>З. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5298-8124</contrib-id><name-alternatives><name xml:lang="en"><surname>Shestakova</surname><given-names>L. A.</given-names></name><name xml:lang="ru"><surname>Шестакова</surname><given-names>Л. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chekini</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Чекини</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8361-6200</contrib-id><name-alternatives><name xml:lang="en"><surname>Ibragimov</surname><given-names>E. K.</given-names></name><name xml:lang="ru"><surname>Ибрагимов</surname><given-names>Э. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7743-0549</contrib-id><name-alternatives><name xml:lang="en"><surname>Puchkova</surname><given-names>E. N.</given-names></name><name xml:lang="ru"><surname>Пучкова</surname><given-names>Е. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0210-3367</contrib-id><name-alternatives><name xml:lang="en"><surname>Lvova</surname><given-names>Yu. E.</given-names></name><name xml:lang="ru"><surname>Львова</surname><given-names>Ю. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Bld. 1, 39 Losinoostrovskaya St., Moscow 107150</italic></p></bio><bio xml:lang="ru"><p><italic>107150 Москва, ул. Лосиноостровская, 39, стр. 1</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7804-5335</contrib-id><name-alternatives><name xml:lang="en"><surname>Rasulov</surname><given-names>R. A.</given-names></name><name xml:lang="ru"><surname>Расулов</surname><given-names>Р. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Bld. 2, 8 Trubetskaya St., Moscow 119991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2 </italic></p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Clinical Hospital “Lapino” of the “Mother and Child” Group of companies</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь «Лапино» группы компаний «Мать и дитя»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Centrosoyuz Hospital of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Больница Центросоюза Российской Федерации</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-10-13" publication-format="electronic"><day>13</day><month>10</month><year>2022</year></pub-date><volume>2</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>21</fpage><lpage>27</lpage><history><date date-type="received" iso-8601-date="2022-10-13"><day>13</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, АБВ-пресс</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://mdonco.abvpress.ru/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://mdonco.abvpress.ru/jour/article/view/41">https://mdonco.abvpress.ru/jour/article/view/41</self-uri><abstract xml:lang="en"><p>Immunotherapy has improved the results of treatment of patients with metastatic colorectal cancer. According to literature, the most cancericidal effect revealed in a microsatellite instability high (MSI-H) tumors. In our case, PD-1/PD-L1/PD-L2 inhibitors (nivolumab) treatment for locally advanced MSI-H colon carcinoma with liver metastasis in 44-year-old patient resulted in tumor regression, so that R0 surgical procedure became possible. Computed tomography scan and pathology report showed complete response, in primary and metastatic tumors. As a result, this allowed to improve the quality of patient’s life.</p></abstract><trans-abstract xml:lang="ru"><p>Иммунотерапия изменила перспективы лечения пациентов с метастатическим колоректальным раком. Данные литературы подтверждают противоопухолевый эффект иммунотерапии у пациентов с колоректальным раком при высоком уровне микросателлитной нестабильности (MSI-H). В представленном клиническом наблюдении показана эффективность проведенного предоперационного лечения блокатором PD-1/PD-L1/PD-L2 (ниволумаб) пациента 44 лет с местно-распространенным олигометастатическим раком ободочной кишки, которое позволило выполнить радикальное хирургическое вмешательство в объеме R0-резекции, достигнуть полного патоморфоза в первичной и метастатической опухоли, а также улучшить качество жизни пациента.</p></trans-abstract><kwd-group xml:lang="en"><kwd>locally advanced colorectal cancer</kwd><kwd>mutation status</kwd><kwd>R0 resection</kwd><kwd>complete pathomorphological response</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>местно-распространенный колоректальный рак</kwd><kwd>мутационный статус</kwd><kwd>иммунотерапия</kwd><kwd>R0-резекция</kwd><kwd>полный патоморфологический ответ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660</mixed-citation><mixed-citation xml:lang="ru">Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Al-Sukhni E., Attwood K., Mattson D.M. et al. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol 2016;23(4):1177–86. DOI: 10.1245/s10434-015-5017-y</mixed-citation><mixed-citation xml:lang="ru">Al-Sukhni E., Attwood K., Mattson D.M. et al. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol 2016;23(4):1177–86. DOI: 10.1245/s10434-015-5017-y</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Sidaway P. Neoadjuvant immunotherapy shows promise. Nat Rev Clin Oncol 2020;17(7):391. DOI: 10.1038/s41571-020-0372-4</mixed-citation><mixed-citation xml:lang="ru">Sidaway P. Neoadjuvant immunotherapy shows promise. Nat Rev Clin Oncol 2020;17(7):391. DOI: 10.1038/s41571-020-0372-4</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Kanani A., Veen T., Søreide K. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg 2021;108(12):1417–25. DOI: 10.1093/bjs/znab342</mixed-citation><mixed-citation xml:lang="ru">Kanani A., Veen T., Søreide K. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg 2021;108(12):1417–25. DOI: 10.1093/bjs/znab342</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Avalone A., Delrio P., Nasti G. et al. Preoperative nivolumab in patients with locally advanced colon cancer (T3 or T4): a window-of-opportunity study (NICOLE). Ann Oncol 2018;29(Suppl 8):viii150–204. DOI: 10.1093/annonc/mdy281.155</mixed-citation><mixed-citation xml:lang="ru">Avalone A., Delrio P., Nasti G. et al. Preoperative nivolumab in patients with locally advanced colon cancer (T3 or T4): a window-of-opportunity study (NICOLE). Ann Oncol 2018;29(Suppl 8):viii150–204. DOI: 10.1093/annonc/mdy281.155</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Chalabi M., Fanchi L.F., Dijkstra K.K. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26(4):566–76. DOI: 10.1038/s41591-020-0805-8</mixed-citation><mixed-citation xml:lang="ru">Chalabi M., Fanchi L.F., Dijkstra K.K. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26(4):566–76. DOI: 10.1038/s41591-020-0805-8</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Zhang X., Wu T., Cai X. et al. Neoadjuvant immunotherapy for MSI-H/ dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol 2022;13:795972. DOI: 10.3389/fimmu.2022.795972</mixed-citation><mixed-citation xml:lang="ru">Zhang X., Wu T., Cai X. et al. Neoadjuvant immunotherapy for MSI-H/ dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol 2022;13:795972. DOI: 10.3389/fimmu.2022.795972</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Salvatore L., Bensi M., Corallo S. et al. Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA Study. J Clin Oncol 2021;39(15_suppl):3511. DOI: 10.1200/JCO.2021.39.15_suppl.3511</mixed-citation><mixed-citation xml:lang="ru">Salvatore L., Bensi M., Corallo S. et al. Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA Study. J Clin Oncol 2021;39(15_suppl):3511. DOI: 10.1200/JCO.2021.39.15_suppl.3511</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Yuki S., Bando H., Tsukada Y. et al. Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J Clin Oncol 2020;38(15_suppl):4100. DOI: 10.1200/JCO.2020.38.15_suppl.4100</mixed-citation><mixed-citation xml:lang="ru">Yuki S., Bando H., Tsukada Y. et al. Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J Clin Oncol 2020;38(15_suppl):4100. DOI: 10.1200/JCO.2020.38.15_suppl.4100</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Cercek A., Lumish M., Sinopoli J. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386(25):2363–76. DOI: 10.1056/NEJMoa2201445</mixed-citation><mixed-citation xml:lang="ru">Cercek A., Lumish M., Sinopoli J. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386(25):2363–76. DOI: 10.1056/NEJMoa2201445</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Trojan J., Stintzing S., Haase O. et al. Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced MSI-H/dMMR rectal cancer. Oncologist 2021;26(12):e2110–e4. DOI: 10.1002/onco.13955</mixed-citation><mixed-citation xml:lang="ru">Trojan J., Stintzing S., Haase O. et al. Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced MSI-H/dMMR rectal cancer. Oncologist 2021;26(12):e2110–e4. DOI: 10.1002/onco.13955</mixed-citation></citation-alternatives></ref></ref-list></back></article>
